Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Aihara T, Takatsuka Y, Ohsumi S, Aogi K, Hozumi Y, Imoto S, Mukai H, Iwata H, Watanabe T, Shimizu C, Nakagami K, Tamura M, Ito T, Masuda N, Ogino N, Hisamatsu K, Mitsuyama S, Abe H, Tanaka S, Yamaguchi T, Ohashi Y. Aihara T, et al. Breast Cancer Res Treat. 2010 Jun;121(2):379-87. doi: 10.1007/s10549-010-0888-x. Breast Cancer Res Treat. 2010. PMID: 20390343 Clinical Trial.
Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.
Ohsumi S, Shimozuma K, Ohashi Y, Shinji M, Hozumi Y, Mukai H, Takatsuka Y, Aihara T. Ohsumi S, et al. Among authors: aihara t. Breast Cancer Res Treat. 2011 May;127(1):143-52. doi: 10.1007/s10549-011-1400-y. Epub 2011 Feb 24. Breast Cancer Res Treat. 2011. PMID: 21347648 Clinical Trial.
The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer.
Mukai H, Aihara T, Yamamoto Y, Takahashi M, Toyama T, Sagara Y, Yamaguchi H, Akabane H, Tsurutani J, Hara F, Fujisawa T, Yamamoto N, Ohsumi S; Japanese Breast Cancer Society. Mukai H, et al. Among authors: aihara t. Breast Cancer. 2015 Jan;22(1):5-15. doi: 10.1007/s12282-014-0563-x. Epub 2014 Sep 9. Breast Cancer. 2015. PMID: 25200171 No abstract available.
Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Aihara T, Yokota I, Hozumi Y, Aogi K, Iwata H, Tamura M, Fukuuchi A, Makino H, Kim R, Andoh M, Tsugawa K, Ohno S, Yamaguchi T, Ohashi Y, Watanabe T, Takatsuka Y, Mukai H. Aihara T, et al. Breast Cancer Res Treat. 2014 Nov;148(2):337-43. doi: 10.1007/s10549-014-3155-8. Epub 2014 Oct 16. Breast Cancer Res Treat. 2014. PMID: 25318924 Clinical Trial.
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group. Takashima T, et al. Lancet Oncol. 2016 Jan;17(1):90-8. doi: 10.1016/S1470-2045(15)00411-8. Epub 2015 Nov 27. Lancet Oncol. 2016. PMID: 26617202 Clinical Trial.
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators. Colleoni M, et al. Lancet Oncol. 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17. Lancet Oncol. 2018. PMID: 29158011 Clinical Trial.
Hormonal Therapy Resistant Estrogen-receptor Positive Metastatic Breast Cancer Cohort (HORSE-BC) Study : Current Status of Treatment Selection in Japan.
Iwamoto T, Taira N, Fujisawa T, Araki K, Sakamaki K, Sangai T, Kikawa Y, Shien T, Takao S, Sato M, Goto Y, Yoshida T, Takahashi M, Aihara T, Mukai H. Iwamoto T, et al. Among authors: aihara t. Acta Med Okayama. 2018 Aug;72(4):369-374. doi: 10.18926/AMO/56172. Acta Med Okayama. 2018. PMID: 30140084 Free article.
485 results